Skip to main content

Table 4 One-year outcomes of the patients with CVSS post-stenting after underwent single antiplatelet plus NOACs or warfarin

From: Safety and efficacy comparison between OACs plus single antiplatelet and dual antiplatelet therapy in patients with cerebral venous sinus stenosis poststenting

Items

NOACs (n = 30)

Warfarin (n = 22)

p-value

Major bleeding events, n (%)

0 (0.0)

0 (0.0)

NA

Non-major bleeding events, n (%)

0 (0.0)

0 (0.0)

NA

VTEs, n (%)

0 (0.0)

0 (0.0)

NA

Intraluminal restenosis

0 (0.0)

0 (0.0)

NA

In-stent thrombosis

0 (0.0)

0 (0.0)

NA

Stent-adjacent stenosis

0 (0.0)

0 (0.0)

NA

Stent displacement

0 (0.0)

0 (0.0)

NA

  1. Abbreviations: NOACs Novel Oral Anticoagulants, VTEs venous thrombotic events; Data are presented as n (%), mean ± SD or median (interquartile range). NA Not applicable